Orange Juice Diet Reduces Colon Cancer Incidence in Animal Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

WASHINGTON-Rats with chemically induced colon cancer that were fed orange juice for 4 weeks had a significantly lower incidence of colon cancer tumors than those receiving water, in a study at Michigan State University, East Lansing. Maurice R. Bennink, PhD, professor of food science and human nutrition, presented the results at the American Institute for Cancer Research 9th Annual Research Conference.

WASHINGTON—Rats with chemically induced colon cancer that were fed orange juice for 4 weeks had a significantly lower incidence of colon cancer tumors than those receiving water, in a study at Michigan State University, East Lansing. Maurice R. Bennink, PhD, professor of food science and human nutrition, presented the results at the American Institute for Cancer Research 9th Annual Research Conference.

Previous studies have shown that certain flavanones, limonoids, and cumarins present in citrus fruits can inhibit chemically induced cancer in animals. But, Dr. Bennink said, “it would be inappropriate to extrapolate from these results with purified citrus phytochemicals that consuming a citrus product such as orange juice will inhibit cancer.” The current study was designed to determine if single-strength, pasteurized orange juice would inhibit azoxymethane-induced colon cancer in male Fisher 344 rats.

The researchers replaced drinking water with orange juice in the diets of the experimental group of 30 rats for 28 weeks. Growth and weight gain were similar in both groups during the study, but feeding orange juice to the rats reduced tumor incidence by 22%.

Tropicana Products, Inc. provided Tropicana Pure Premium orange juice and financial support for the study.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.